Capricor Therapeutics (NASDAQ:CAPR) Issues Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.59), FiscalAI reports.

Capricor Therapeutics Price Performance

CAPR stock traded down $0.98 during midday trading on Tuesday, hitting $8.87. The stock had a trading volume of 4,307,808 shares, compared to its average volume of 3,158,908. The firm has a market cap of $515.70 million, a price-to-earnings ratio of -3.62 and a beta of 0.80. The business has a 50-day moving average of $8.09 and a two-hundred day moving average of $20.13. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CAPR. Roth Capital cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research report on Monday, July 27th. HC Wainwright cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 30th. Wall Street Zen lowered shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Finally, Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics has an average rating of “Hold” and an average price target of $30.25.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.